Stock Region Penny Picks
Biotech on Fire: A New Wave of Hope?
Stock Region Penny Picks Watchlist Newsletter: Thursday, February 5, 2026
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: This is not financial advice. The content of this newsletter is for informational and entertainment purposes only. All opinions expressed here are our own and should not be taken as a recommendation to buy or sell any security. Always do your own research before making any investment decisions. Trading stocks involves risk, and you could lose your entire investment.
What a day yesterday was. We saw some truly fascinating moves, from biotech breakthroughs to tech earnings that have everyone talking. Let’s dive into the tickers that are lighting up the screens this morning.
Biotech on Fire: A New Wave of Hope?
The biotech sector was buzzing, and a few names stood out with some potentially huge developments.
$CANF - Can-Fite BioPharma: This one is just incredible. Can-Fite announced that a patient with severe liver cirrhosis was able to successfully undergo a liver transplant after being treated with their drug, Namodenoson. For a small-cap biotech, this kind of human result is monumental. It provides powerful validation for their platform and could be a major step toward addressing a huge unmet medical need. Definitely keeping a close eye on this one.
$PPCB - Propanc Biopharma: Speaking of game-changers, Propanc came out swinging with an update on their PRP therapy. They’re positioning it to take on standard treatments for pancreatic cancer, a market they estimate at over $3 billion. That’s a bold claim, but you love to see that ambition. Pancreatic cancer is notoriously difficult to treat, and any company making credible strides in this area deserves our attention. This could be a long road, but the potential is undeniable.
$AIM - AIM ImmunoTech: More good news on the pancreatic cancer front. AIM reported positive interim data from their Phase 2 study combining Ampligen with AstraZeneca’s Imfinzi. Seeing a small company like AIM working alongside a giant like AstraZeneca is always a bullish sign in my book. It adds a layer of credibility. Positive Phase 2 results are a critical milestone that can really de-risk a drug’s development path. This puts AIM firmly on the map for anyone watching the oncology space.
Tech and Expansion: The Movers and Shakers
Beyond the lab coats and microscopes, we saw some interesting strategic moves from companies looking to grow their footprint.
$TEAD - Teads: Here’s a smart partnership. Teads is teaming up with Google TV to expand its Connected TV (CTV) advertising reach. This is all about getting in front of more eyeballs. As more of us cut the cord and move to streaming, the home screen of our smart TVs becomes prime real estate. This deal puts Teads right where the action is, which could be a significant revenue driver down the line.
$CETX - Cemtrex: Cemtrex just closed its acquisition of Richland Industries, expanding its industrial services into the Southeast. This might not be as flashy as a new cancer drug, but these are the kinds of solid, strategic moves that build long-term value. Acquisitions like this mean more revenue, a larger footprint, and better market positioning. It shows management is focused on growth, and we’re here for it.
The Elephant In The Room: Amazon’s Earnings
$AMZN - Amazon: And then there was Amazon. The big one. The numbers came in after the bell, and it was a mixed bag that tells a fascinating story. They barely missed on earnings per share ($1.95 vs. $1.97 expected). But—and this is a big but—they beat on revenue, pulling in a staggering $213.4 billion.
So, what does this mean? The slight earnings miss might spook some, but the revenue beat tells me the Amazon machine is still humming along beautifully. People are still buying, and the company’s sales are growing at a healthy clip year-over-year. The market can be fickle with these mega-caps, so expect some volatility. However, the top-line growth shows the core business remains incredibly strong. We’re not worried; we’re watching to see if any dips present a buying opportunity.
That’s the rundown for today! Keep your heads on a swivel, manage your risk, and look for those opportunities.
Talk soon,
Your Friends at Stock Region
Final Disclaimer: Remember, investing in the stock market carries risks. The stocks mentioned in this newsletter are for discussion purposes only. We may or may not hold positions in these stocks. Please conduct your own due diligence and consult with a financial advisor before making any investment decisions.